In 2024, the U.S. Drug Enforcement Administration (DEA) indicated that they intend to reclassify cannabis as being a Schedule III drug. This rescheduling will realize that cannabis has legitimate healthcare needs and will help open the doorway to analysis on other prospective remedy employs.